When your care team starts discussing treatment for head and neck cancer, you may hear the term PD-L1, which stands for programmed death-ligand 1. Testing for PD-L1 helps your oncologist determine ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
A phase 2 study of HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy as first-line therapy in advanced squamous non-small cell lung cancer. Clinical outcomes and ...
Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...
Olink proteomics analysis to identify biomarkers of radiation- and immunotherapy-induced pneumonitis. Molecular markers associated with survival in PD-L1– high non-small cell lung cancer treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results